weak global demand, especially exports of Epichlorohydrin decreased caused by lockdown restrictions in several countries. Analysis of Cost and Expenses 1. In Q2 2020, Cost of sales was 2,898 MTHB
Services revenue OOH Advertising segment revenue Transit media revenue Office and Other media revenue Digital Services segment revenue Other income Cost of sales Cost-to-sales ratio gross profit gross
) -12.4% Interest income 115 79 36 +45.6% Cost of sales and services 3,855 3,956 (101) -2.6% SG&A expenses 256 238 18 +7.6% EBIT 368 302 66 +21.9% Interest and Tax expenses 126 59 67 +113.6% Share of profit
Total Revenues 4,432 4,888 -455 -9.32% Sales and service income 4,244 4,747 -503 -10.60% Gains on Exchange rate 108 52 56 107.01% Other Income 80 88 -8 -9.09% Cost of Sales and Services 3,848 4,214 -366
in 2Q18. This was mostly due to an increase in revenues from Inpatients, Outpatients and IVF patients. The Company reported Cost of Hospital Operations (including Depreciation and Amortization) of Baht
40 65 Total Debt to Equity 0.48 0.16 * calculated by using earning four previous consecutive quarters ** based on only cost of medicine & medical supplies
) -34.6 Cost of service 2,591 2,393 198 8.3 Selling and administrative expenses 303 276 27 9.8 Finance cost 328 312 16 5.1 Interest expense from the MRT Purple Line Project 94 108 (14) -13.0 Total expenses
) (7.2) (682%) (8.2) (587%) Net Profit/(Loss) from the period attribute to equity holders of the Company (53.0) (4.9) (982%) (3.5) (1,414%) For the nine-month ended 30 September 2017 NPP Consolidated PL
equity holders of the Company (36.7) (3.5) 948.6% (45.9) (20.0%) For the six-month ended 30 June 2018 Consolidated Profit & Loss of NPPG (THAILAND) PCL., Unit : Million Baht Quarter 2 Year 2018 Quarter 2